Skip to main content

Table 3 Probability of one treatment being better

From: International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol

Observed 3-year EFSObserved HRP (HR <1.00)P (HR <0.81)P (HR >1.21)
VIDEDifferenceVDC/IENumber of eventsHRln (HR)
0.700.000.701801.000.000.500.070.10
0.700.050.751650.81−0.210.920.500.00
0.70−0.050.651951.210.190.090.000.50
0.700.0250.7251730.90−0.100.750.230.03
0.70− 0.0250.6751881.100.100.250.020.27
  1. EFS event-free survival, HR hazard ratio, VDC/IE vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide, VIDE vincristine, ifosfamide, doxorubicin and etoposide